News
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, November 3, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners...
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
NEW YORK, November 02, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced completion of enrollment of the first...
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
NEW YORK, October 26, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first...
Article: BioSpace published an article on Tiziana’s plan to submit an IND for Intranasal Alzheimer’s Treatment
Tiziana Plans IND for Intranasal Alzheimer's Treatment with Promising CNS History
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
New York- October 19, 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will be participating in The ThinkEquity Conference, which will take place on October...
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer’s Disease Patients
Company continues to advance foralumab in CNS-related inflammatory diseases NEW YORK, Oct. 12, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
New York, September 29, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit“Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
New York, September 23, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its...
Article: ALS Association Funds Study of Foralumab Nasal Spray
ALS News Today published an article about the ALS Association funding a study into Foralumab Nasal Spray
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, September 21, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners...
Article: Second SPMS Patient Given Foralumab Continues to Improve
Multiple Sclerosis News Today has published an article providing an update on the second SPMS patient given Foralumab
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and enduranceThe patient showed clinically significant improvement in the Expanded Disability Status Scale (EDSS).The 6-month PET imaging will occur in Q4 2022 to...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, September 16, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners...
Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis
Prestigious ALS Association grant awarded to BWH to study the utility of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis New York, September 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
New York, September 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, August 25, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, August 17, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited,...
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
- Study conducted in animal models of Alzheimer’s disease finds restored microglia homeostasis and improvement in cognition - New York, August 1, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
New York, July 18, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has appointed Matthew Davis, MD, RPh as its Chief...
Tiziana Life Sciences Announces Resignation of CEO
New York, July 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary...
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice New York, June 17, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery,...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, June 10, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited,...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...